Latest Regulatory Risks News

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.

Cobalt Blue has secured a US$150,000 contract to deliver key technical work for Glomar Minerals’ planned US polymetallic nodule refinery. The work takes Project Infinity into a formal Preliminary Economic Analysis, although the project remains at an early evaluation stage and its cost estimates carry a wide accuracy range.

Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.

Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.

Klevo Group Limited (ASX:KLV) has announced a pro-rata entitlement issue of Loyalty Options to raise approximately $3.1 million, aiming to accelerate its credit capabilities and expand its Mastercard program in Asia.

Hawk Resources has cleared a major regulatory hurdle with the WA Minister for Aboriginal Affairs approving a Mining Entry Permit for its Olympus scandium project, paving the way for exploration activities to begin by September 2026, pending final government consents.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

BKI Investment Company has expanded its risk disclosure, outlining significant market, income, operational, and regulatory risks that could influence its financial outcomes and shareholder dividends.

Teaminvest Private Group (ASX: TIP) posted a 19% increase in statutory profit for FY26, driven by strong active portfolio growth and disciplined capital allocation, while preparing to acquire Intelligent Investor in an earnings accretive deal.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

NobleOak Life delivered robust FY26 results with in-force premiums climbing 18% to $549.2 million and underlying NPAT up 15%, driven by strong market share gains and operational efficiency.